Wednesday, August 6, 2014
AUSTIN – Texas Attorney General Greg Abbott and 41 other state attorneys general today secured a $35 million agreement with drug maker Wyeth Pharmaceuticals Inc., a wholly owned subsidiary of Pfizer Inc. The agreement resolves a multistate investigation against Wyeth for unlawfully promoting its immunosuppressive drug Rapamune.
Under the settlement agreement, Pfizer must pay the State of Texas a total of $2.387 million. The agreement orders $1.591 million of the settlement funds to be disbursed to the General Revenue or the Supreme Court Judicial Fund, as appropriate, pursuant to Texas Government Code Sec. 402.007. The remaining funds will reimburse the State’s legal fees.
|State of Texas vs. Wyeth Pharmaceuticals|
According to the states’ investigation, Wyeth violated state consumer protection laws by misrepresenting the uses and qualities of Rapamune. State and federal law generally prohibits pharmaceutical manufacturers from marketing their drugs for “off-label” uses that have not been approved by the U.S. Food and Drug Administration (FDA).
Today’s judgment requires Pfizer to ensure that its marketing and promotional practices do not unlawfully promote Rapamune or any Pfizer product. Among its terms, the judgment prohibits Pfizer from the following actions:
Texas and Oregon led the Executive Committee, which also includes attorneys general from California, Florida, Illinois, Maryland, New York, North Carolina, and Pennsylvania.
Also participating in the settlement are Alabama, Arizona, Arkansas, Colorado, Delaware, District of Columbia, Georgia, Hawaii, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Dakota, Ohio, Oklahoma, South Dakota, Tennessee, Utah, Virginia, Washington, and Wisconsin.